Pagliano Pasquale, Ascione Tiziana, Carleo Maria Aurora, Boccia Giovanni, De Caro Francesco, Tortora Fabio
Department of Infectious Diseases, AORN dei Colli, D. Cotugno Hospital, Naples, Italy.
Institute of Hygiene, University of Salerno, Italy.
Infez Med. 2016 Sep 1;24(3):245-9.
Incidence of brain infections in Human Immunodeficiency Virus (HIV) positive patients is reduced after the availability of current high active antiretroviral therapy (HAART). Herpes Simplex Virus type 2 (HSV-2) is an infrequent cause of encephalitis in HIV patients despite it is frequently involved in sexual transmitted infections. Here, we report a case of HSV-2 encephalitis occurring in a patient without full suppression of HIV replication within the brain. A 38 year-old HIV infected man was admitted to our department because of recurrent generalized seizure and fever during the previous 24 hours. Eight months before our observation the patient was switched from a protease inhibitor based regimen to a rilpivirine-based regimen without any evidence of HIV-RNA replication in the plasma. When the patient was admitted in our hospital, he was febrile and moderately confused, no deficit of cranial nerves was reported, motility was conserved, but he was unable to walk. Laboratory examinations performed at admission demonstrated an increase of cerebrospinal fluid (CSF) protein and cells with lymphocyte prevalence, and normal CSF glucose. HSV-2-DNA and HIV-RNA were present within CSF at admission. Nuclear Magnetic Resonance imaging of the brain revealed lesions of the medial part of both temporal lobes including hippocampus without any sign of bleeding. A 21-day course of acyclovir therapy was administered with consistent improvement of clinical findings and disappearance of HSV-2-DNA within CSF. After the episode, HAART was switched to a regimen with high CSF penetrability containing abacavir, lamivudine, darunavir and ritonavir. Twelve months after HSV-2 encephalitis neurologic evaluation was normal, but symptoms of depression were reported, HIV-RNA remained undetectable both in the plasma and CSF, and CD4+ lymphocytes were above 500/μL. No opportunistic infection was reported. Patients switched to regimen well tolerated such those containing rilpivirine, that have poor drug concentration within CSF could be considered at risk for opportunistic infection of the brain. Further larger investigation needs to confirm this finding.
在当前高效抗逆转录病毒疗法(HAART)应用后,人类免疫缺陷病毒(HIV)阳性患者脑部感染的发生率有所降低。2型单纯疱疹病毒(HSV-2)在HIV患者中虽常与性传播感染有关,但却是罕见的脑炎病因。在此,我们报告一例在脑内HIV复制未得到完全抑制的患者中发生的HSV-2脑炎病例。一名38岁的HIV感染男性因在过去24小时内反复全身性癫痫发作和发热而入住我科。在我们观察前八个月,该患者从基于蛋白酶抑制剂的治疗方案转换为基于利匹韦林的治疗方案,血浆中无HIV-RNA复制迹象。患者入院时发热且有中度意识模糊,未报告有颅神经功能缺损,肢体活动保留,但无法行走。入院时进行的实验室检查显示脑脊液(CSF)蛋白和细胞增多,以淋巴细胞为主,CSF葡萄糖正常。入院时CSF中存在HSV-2-DNA和HIV-RNA。脑部核磁共振成像显示双侧颞叶内侧包括海马区有病变,无出血迹象。给予21天的阿昔洛韦治疗,临床症状持续改善,CSF中HSV-2-DNA消失。此次发作后,HAART转换为一种具有高CSF渗透性的治疗方案,包含阿巴卡韦、拉米夫定、达芦那韦和利托那韦。HSV-2脑炎发作十二个月后,神经学评估正常,但报告有抑郁症状,血浆和CSF中HIV-RNA均未检测到,CD4 +淋巴细胞高于500/μL。未报告有机会性感染。转换为对含利匹韦林等耐受性良好但CSF中药物浓度低的治疗方案的患者,可能被视为有脑部机会性感染风险。需要进一步更大规模的研究来证实这一发现。